UNSPSC 51111913: Paclitaxel ceribate

This classification denotes a taxane compound and taxane-site binding agent C51H57NO18, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B3C86E80A0, chemically known as 7.beta.-((2rs)-2,3-dihydroxypropoxycarbonyloxy)-1-hydroxy-9-oxo-5.beta.,20-epoxytax-11-ene-2.alpha.,4,10.beta.,13.alpha.-tetrayl 4,10-diacetate 2-benzoate 13-((2r,3s)-3-benzamido-2-hydroxy-3-phenylpropanoate), but more generally known as paclitaxel ceribate, which bears US NIH Compound Identifier 16760673.

UNSPSC 51111913 Paclitaxel ceribate is a Commodity code representing a specific pharmaceutical product — a paclitaxel formulation — that state and local health agencies procure for medical use. The code reflects procurement activity in state pharmacy benefit programs and health plan administration rather than manufacturing or wholesale distribution. State and local issuing bodies using this code include health and human services departments managing pharmacy benefits for state employees, retirees, and Medicaid populations, as well as public health agencies supporting treatment protocols.

The Texas Health and Human Services Commission posted Request for Information RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. This RFI represents exploratory procurement to establish direct contracting relationships between the state's pharmacy benefit program and pharmaceutical manufacturers, bypassing traditional pharmacy benefit managers and group purchasing organizations. The state is gathering information on vendors' experience with direct contracting for self-insured employers and government health plans, their ability to negotiate net pricing models, and their capacity to implement outcomes-based agreements. No award value, budget range, or binding timeline accompanies this RFI, as it functions as a preliminary market-intelligence mechanism to inform subsequent formal RFP development. The RFI does not specify set-aside designations or disadvantaged enterprise restrictions.